Difference between revisions of "Cisplatin (Platinol)"
Jump to navigation
Jump to search
m (→Also known as) |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: [[vesicant]] (concentration ≥0.5 mg/mL)/[[irritant]] (concentration less than 0.5 mg/mL) | <br>Extravasation: [[vesicant]] (concentration ≥0.5 mg/mL)/[[irritant]] (concentration less than 0.5 mg/mL) | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is established ''(work in progress)''== | ==Diseases for which it is established ''(work in progress)''== | ||
| Line 59: | Line 59: | ||
*[[Thymoma]] | *[[Thymoma]] | ||
*[[Upper tract urothelial carcinoma]] | *[[Upper tract urothelial carcinoma]] | ||
| + | *[[Urothelial carcinoma]] | ||
*[[Vulvar cancer]] | *[[Vulvar cancer]] | ||
</div> | </div> | ||
| Line 64: | Line 65: | ||
==Patient drug information== | ==Patient drug information== | ||
*[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de6302d5-85f0-4116-a709-57826c2c84fe Cisplatin (Platinol) package insert]<ref name="insert"></ref> | *[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de6302d5-85f0-4116-a709-57826c2c84fe Cisplatin (Platinol) package insert]<ref name="insert"></ref> | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/cisplatin.aspx Cisplatin (Platinol) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/cisplatin.aspx Cisplatin (Platinol) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/cisplatin-patient-drug-information Cisplatin (Platinol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cisplatin-patient-drug-information Cisplatin (Platinol) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/cisplatin-patient-drug-information Cisplatin (Platinol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cisplatin-patient-drug-information Cisplatin (Platinol) patient drug information (UpToDate)]</ref> | ||
| Line 71: | Line 72: | ||
*2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic [[testicular cancer|testicular tumors]] who have already received appropriate surgical and/or radiotherapeutic procedures. ''(No supporting studies are cited)'' | *2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic [[testicular cancer|testicular tumors]] who have already received appropriate surgical and/or radiotherapeutic procedures. ''(No supporting studies are cited)'' | ||
*2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic [[ovarian cancer|ovarian tumors]] who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL and cyclophosphamide. ''(Based on Wiernik et al. 1992a)'' | *2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic [[ovarian cancer|ovarian tumors]] who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL and cyclophosphamide. ''(Based on Wiernik et al. 1992a)'' | ||
| − | *2010-09-02 (oldest label available at Drugs @ FDA): PLATINOL, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received PLATINOL therapy. ''(Based on Wiernik et al. 1992a)'' | + | *2010-09-02 (oldest label available at Drugs @ FDA): PLATINOL, as a single agent, is indicated as secondary therapy in patients with metastatic [[Ovarian cancer|ovarian tumors]] refractory to standard chemotherapy who have not previously received PLATINOL therapy. ''(Based on Wiernik et al. 1992a)'' |
*2010-09-02 (oldest label available at Drugs @ FDA): Indicated as a single agent for patients with transitional cell [[bladder cancer]] which is no longer amenable to local treatments, such as surgery and/or radiotherapy. ''(No supporting studies are cited)'' | *2010-09-02 (oldest label available at Drugs @ FDA): Indicated as a single agent for patients with transitional cell [[bladder cancer]] which is no longer amenable to local treatments, such as surgery and/or radiotherapy. ''(No supporting studies are cited)'' | ||
| + | |||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*1978-12-19: EURD | *1978-12-19: EURD | ||
| Line 224: | Line 226: | ||
[[Category:Transformed lymphoma medications]] | [[Category:Transformed lymphoma medications]] | ||
[[Category:Upper tract urothelial carcinoma medications]] | [[Category:Upper tract urothelial carcinoma medications]] | ||
| + | [[Category:Urothelial carcinoma medications]] | ||
[[Category:Vulvar cancer medications]] | [[Category:Vulvar cancer medications]] | ||
Latest revision as of 01:04, 29 June 2024
General information
Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]
Route: IV, intracavitary (intraperitoneal)
Extravasation: vesicant (concentration ≥0.5 mg/mL)/irritant (concentration less than 0.5 mg/mL)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is established (work in progress)
- Bladder cancer
- Malignant pleural mesothelioma
- Nasopharyngeal carcinoma
- Non-Hodgkin lymphoma
- Osteosarcoma
- Ovarian cancer
- Testicular cancer
Diseases for which it is used
- Adrenocortical carcinoma
- Anal cancer
- Breast cancer
- Carcinoma of unknown primary
- Cervical cancer
- Cholangiocarcinoma
- Cutaneous basal cell carcinoma
- Cutaneous squamous cell carcinoma
- Endometrial cancer
- Esophageal cancer
- Gallbladder cancer
- Gastric cancer
- Head and neck cancer
- Hepatoblastoma
- Classical Hodgkin lymphoma
- Low-grade glioma
- Melanoma
- Medulloblastoma
- Multiple myeloma
- Neuroblastoma
- Non-Hodgkin lymphoma
- Non-small cell lung cancer
- Pancreatic cancer
- Penile cancer
- Small cell lung cancer
- Soft tissue sarcoma
- Thymoma
- Upper tract urothelial carcinoma
- Urothelial carcinoma
- Vulvar cancer
Patient drug information
- Cisplatin (Platinol) package insert[1]
- Cisplatin (Platinol) patient drug information (Chemocare)[3]
- Cisplatin (Platinol) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1978-12-19: Initial FDA approval
- 2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. (No supporting studies are cited)
- 2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL and cyclophosphamide. (Based on Wiernik et al. 1992a)
- 2010-09-02 (oldest label available at Drugs @ FDA): PLATINOL, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received PLATINOL therapy. (Based on Wiernik et al. 1992a)
- 2010-09-02 (oldest label available at Drugs @ FDA): Indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. (No supporting studies are cited)
History of changes in EMA indication
- 1978-12-19: EURD
History of changes in PMDA indication
- 2012-02-22: New additional indication and a new dosage for the treatment of biliary tract cancer.
Also known as
- Code name: NSC-119875
- Generic names: CDDP, cis-diamminedichloroplatinum III, cis-platinum, cisplatinum, DACP, DDP
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Abiplatin | Axiplat | Biocisplatinum | Bioplatino | Blastolem | Briplatin | Brisplatin | C-Platin |
| Ceplatin | Ciplatan | Ciplexal | Cis-GRY | Cismaplat | Cispatin | Cisplamerck | Cisplan |
| Cisplasol | Cisplatex | Cisplatine | Cisplatino | Cisplatyl | Cisteen | Citoplatino | Citosin |
| Cysplatyna | Cytoplatin | Docistin | Elvecis | Fauldcispla | Ifapla | Kemoplat | Lederplatin |
| Metaplatin | Neoplat | Neoplatin | Noveldexis | Oncoplatin AQ | Peyrone's Chloride | Peyrone's Salt | Placis |
| Plastistil | Platamin | Platamine | Platiblastin | Platicis | Platidiam | Platikem | Platil |
| Platimit | Platin | Platinex | Platinil | Platino II Filaxis | Platinol | Platinox | Platinoxan |
| Platiran | Platistil | Platistin | Platistine | Platosin | Randa | Romcis | Sicatem |
| Sinplatin | Sisplanil | Tecnoplatin | Tisplal | Unistin | |||
References
Categories:
- Drugs
- Intravenous medications
- Intracavitary medications
- Vesicant
- Irritant
- Platinum agents
- Alkylating agents
- Carcinoma of unknown primary medications
- Adrenocortical carcinoma medications
- Anal cancer medications
- Anaplastic large cell lymphoma medications
- Cutaneous basal cell carcinoma medications
- Bladder cancer medications
- Breast cancer medications
- Cervical cancer medications
- Cholangiocarcinoma medications
- Cutaneous squamous cell carcinoma medications
- Diffuse large B-cell lymphoma medications
- Endometrial cancer medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Esophageal squamous cell carcinoma medications
- Extranodal NK- and T-cell lymphoma, nasal type medications
- Gallbladder cancer medications
- Gastric cancer medications
- Head and neck cancer medications
- Hepatoblastoma medications
- Classical Hodgkin lymphoma medications
- Low-grade glioma medications
- Low-grade glioma, pediatric medications
- Mantle cell lymphoma medications
- Medulloblastoma medications
- Melanoma medications
- Malignant pleural mesothelioma medications
- Multiple myeloma medications
- Nasopharyngeal carcinoma medications
- Neuroblastoma medications
- Neuroendocrine carcinoma medications
- NK- and T-cell lymphoma medications
- Non-small cell lung cancer medications
- Non-small cell lung cancer, nonsquamous medications
- Non-small cell lung cancer, squamous medications
- Oropharyngeal cancer medications
- Osteosarcoma medications
- Ovarian cancer medications
- Pancreatic cancer medications
- Penile cancer medications
- Peripheral T-cell lymphoma medications
- Primary mediastinal B-cell lymphoma medications
- Small cell lung cancer medications
- Soft tissue sarcoma medications
- Testicular cancer medications
- Thymoma medications
- Transformed lymphoma medications
- Upper tract urothelial carcinoma medications
- Urothelial carcinoma medications
- Vulvar cancer medications
- FDA approved in 1978
- EMA approved in 1978
- WHO Essential Cancer Medicine